8 月 30 日 CVU mini 的录音现已发布
Thank you to all who attended our recent CVU miniseries event COVID-19：6 个月及以上儿童的感染和疫苗 on Tuesday 30th August 2022.
This interactive webinar provided an update on:
- 6 个月以上儿童感染 COVID-19：墨尔本的经验
- 针对 6 个月以上澳大利亚儿童的 COVID-19 疫苗建议
- 儿童 COVID-19 疫苗的安全性
A recording of this event is now available via our education portal.
To access this recording please follow the link below:
八月 CVU 迷你活动现已开放报名
MVEC’s next Clinical Vaccinology Update (CVU) mini event on COVID-19: infection and vaccines in children aged 6 months and over will take place virtually on Tuesday 30th August. This CVU mini will provide an update on:
- 针对 6 个月以上澳大利亚儿童的 COVID-19 疫苗建议
- 儿童 COVID-19 疫苗的安全性
- COVID-19 vaccine rollout logistics
The event program and link to register will be available shortly via our Events page or via the link below.
更新了 MVEC 免疫参考页面：儿童和青少年的 COVID-19 疫苗接种页面
MVEC’s COVID-19 vaccination in children and the adolescent reference page has been updated to include the current recommendations for children under 5 years of age. This resource details:
- Recommended COVID-19 vaccine schedule information for children and adolescents aged ≥ 6 months
- Information on the efficacy and side effects of COVID-19 vaccination in the paediatric population
- Links to current ATAGI COVID-19 vaccine recommendations in the various paediatric and adolescent age groups
要查看完整页面，请点击以下链接：
ATAGI 关于 5 岁以下儿童使用 COVID-19 疫苗的建议
ATAGI have now recommended COVID-19 vaccination for some children aged 6 months – 5 years. Eligible groups include those with severe immunocompromise, a disability with severe or complex health needs, or those with multiple/complex health conditions that increase the risk of severe COVID-19 disease.
A paediatric formula of the Moderna COVID-19 vaccine has been approved by the TGA in this age group for children in the groups mentioned above. A primary two-dose schedule, 8 weeks apart is recommended, with the dose being 25mcg. Children in this age group with severe immunocompromise are recommended to complete a 3-dose primary schedule.
基于一系列因素，ATAGI 目前不建议不属于上述类别的 6 个月至 5 岁儿童接种 COVID 疫苗。
随着替代品牌或变体 COVID-19 疫苗在这个年龄段可用，或者如果出现流行病学变化（例如出现新的令人担忧的变体），建议可能会发生变化。
To read the recommendations in full please follow the link below.
ATAGI recommendations on COVID-19 vaccine use in children aged 6 months to <5 years
COVID-19 疫苗对超过 200,000 名澳大利亚儿童的安全性：来自 AusVaxSafety 的令人放心的数据
New AusVaxSafety research which analysed 392,268 survey responses via AusVaxSafety’s national active safety surveillance system between July 2021 and May 2022, has found that Australian children aged 5-15 years report fewer side effects in the days following mRNA COVID-19 vaccination than those reported in clinical trials and published safety data.
Importantly, fever was reported low in the youngest age group, comparable to that seen following annual influenza vaccination. Additionally, there were also no self-reported cases of myocarditis and pericarditis identified in the study.
AusVaxSafety will commence surveillance in children aged 6 months to 5 years once COVID-19 vaccines become available in this age group.
To access the research in full, click on the link below.
Safety of COVID-19 vaccines in >200,000 Aussie kids: reassuring data from AusVax安全
Flinders University Alumni publication featuring A/Prof Nigel Crawford: Providing the vital boost for us to fight COVID-19
MVEC’s Associate Professor Nigel Crawford was featured in the Flinders University College of Medicine and Public Health Alumni magazine regarding his significant contribution to Australia’s COVID-19 vaccine rollout. As the current chair of the Australian Technical Advisory Group for Immunisation (ATAGI), Nigel discusses his role in steering Australia’s uptake of COVID-19 vaccines, including effective communication and the ability to remain flexible when responding to and adapting vaccine advice for the general public.
To read the full article, follow the link below.
Registrations opening soon for our next CVU mini August event
MVEC’s next Clinical Vaccinology Update (CVU) mini event on COVID-19: infection and vaccines in children aged 6 months and over will take place virtually in August, with the date to be announced shortly. This CVU mini will provide an update on:
- 针对 6 个月以上澳大利亚儿童的 COVID-19 疫苗建议
- 儿童 COVID-19 疫苗的安全性
The event program and link to register will be available shortly via our Events page or via the link below.
对话：针对 5 岁以下儿童的 COVID 疫苗即将问世。这是父母需要知道的
治疗用品管理局 (TGA) 已临时批准了适用于 6 个月以上儿童的 Moderna COVID-19 疫苗儿科剂量。
MVEC 的 Daryl Cheng 博士和 Margie Danchin 副教授探讨了在澳大利亚向该人群推出 Moderna 疫苗之前父母需要了解的内容，包括疫苗的安全性和有效性以及在该年龄段接种疫苗的好处和影响本文。
要阅读全文，请点击以下链接：
对话：针对 5 岁以下儿童的 COVID 疫苗即将问世。这是父母需要知道的
VicSIS 更新 - 服务已更改
从 2022 年 7 月起，VicSIS（维多利亚专家免疫服务网络）提供的服务发生了变化。 VicSIS 诊所的数量及其地点已经减少，成人服务现在仅在 Barwon Health、Austin Health、Monash Health 和 Peter MacCallum 癌症中心提供。由于这些变化，预约的等待时间可能会更长，因此应告知患者。
此外，VicSIS 不再资助支持儿科 COVID-19 疫苗接种。需要专家建议的 15 岁及以下儿童可以通过皇家儿童医院和莫纳什健康中心现有的专家免疫诊所进行检查。这些服务的推荐应继续通过 VicSIS eReferral 门户提交。
有关 VicSIS 的更多信息，请参阅以下链接：
ATAGI 更新了冬季剂量 COVID-19 疫苗的建议
ATAGI 扩大了推荐接受 COVID-19 冬季加强剂量的人群，现在包括：
- 任何 50 岁及以上的成年人（包括原住民和托雷斯海峡岛民）
- 16 岁及以上的老年护理或残疾护理居民
- 16 岁及以上患有严重疾病的人 免疫功能低下， 残疾或复杂的健康需求，或患有多种合并症的人，这可能会增加较差结果的可能性。
此外，任何希望降低 COVID-19 感染可能性的 30-49 岁成年人也可以接受冬季加强剂量。之前 COVID-19 感染或之前加强剂量与冬季加强剂量之间的推荐间隔为 3 个月。
ATAGI 关切地注意到，加强剂量的覆盖范围（第一剂和冬季剂）对符合条件的人群来说并不理想，并强调了疫苗接种在预防严重感染和住院方面的重要性。
要完整阅读更新后的建议，请单击以下链接：